课件:老年人低钠血症的诊治.pptVIP

  1. 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
  2. 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  3. 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  4. 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  5. 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  6. 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  7. 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
课件:老年人低钠血症的诊治.ppt

急性症状性低钠血症是非常危重的临床状态。 低钠,水平衡驱使水透过脑细胞膜致细胞肿胀。由于颅骨的限制性,急性低钠可致严重脑水肿,脑疝,和心肺骤停。 随时间延长,脑内可发生适应性变化。最初1-3小时,细胞外液移动至脑脊液,然后进入循环。 缓慢适应过程中,脑细胞逐出钾离子和有机溶质,以减少细胞内渗透浓度及脑水肿。 持续低钠超过48小时,其它有机渗透分子(磷酸肌酸、肌醇、和氨基酸如谷氨酸盐)排出,致使脑细胞失水,脑容量恢复至接近正常,但这是以脑细胞丢失钾和其他有机渗透分子为代价。 * * Of 106 randomized subjects (lixivaptan,?n=54; placebo,?n=52), 101 received treatment, and 73 completed both the treatment period and follow-up periods of the study (Figure 1). In both treatment arms, the most common reason for discontinuation was withdrawal of consent. Baseline characteristics of subjects who received the study drug have been summarized in?Table 1. Most subjects were white and from North America or Western Europe. More than half of the subjects were? 65 years of age. Although baseline characteristics were generally well balanced between groups, significantly fewer subjects in the lixivaptan group were on fluid restriction at baseline compared with those in the placebo group (20 (37.0%) vs. 34 (65.4%) subjects, respectively;?P=0.004). Numerous symptoms of hyponatremia were apparent at baseline, most commonly fatigue and slowing of mental faculties (Figure 2). The underlying cause of SIADH was not investigated prospectively in the study. At baseline, eight patients (8.0%) had lung cancer, two (2.0%) had human immunodeficiency virus infection, and 33 (33%) were receiving drugs known to induce hyponatremia, including carbamazepine (7.0%), cyclophosphamide (1.0%), phenothiazines (2.0%), selective serotonin reuptake inhibitors (10.0%), thiazides (6.0%), and monoamine oxidase inhibitors (7.0%). Of 106 randomized subjects (lixivaptan,?n=54; placebo,?n=52), 101 received treatment, and 73 completed both the treatment period and follow-up periods of the study (Figure 1). In both treatment arms, the most common reason for discontinuation was withdrawal of consent. Baseline characteristics of subjects who received the study drug have been summarized in?Table 1. Most subjects were white and from North America or Western Eu

文档评论(0)

iuad + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档